Meyahealth
Home
ENES
HomeGeneticsGeneUCHL1 gene
Back to Gene

UCHL1 gene

Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

UCHL1 gene

The UCHL1 gene provides instructions for making an enzyme that acts as part of the cell's quality control system to degrade unneeded or damaged proteins.

Normal Function

The UCHL1 gene provides instructions for making an enzyme called ubiquitin carboxyl-terminal esterase L1, which is found in nerve cells throughout the brain. This enzyme is involved in the ubiquitin-proteasome system, which breaks down damaged, misshapen, or excess proteins.

The enzyme appears to have two primary functions:

  • Hydrolase activity: Removes and recycles ubiquitin molecules from degraded proteins to sustain the degradation process.
  • Ligase activity: Links ubiquitin molecules together to tag proteins for disposal.

Health Conditions Related to Genetic Changes

Parkinson's disease

Variations in the UCHL1 gene have been studied for their potential role in Parkinson's disease, a condition characterized by progressive problems with movement and balance.

  • Ser18Tyr (S18Y) polymorphism: A common variation that reduces the ligase activity of the enzyme. Some studies suggest this may help protect against Parkinson's disease, particularly in young adults, though findings are inconsistent.
  • Ile93Met (I93M) mutation: A rare mutation that leads to decreased hydrolase activity. This may disrupt the ubiquitin-proteasome system, causing toxic proteins to accumulate and kill nerve cells in the brain. It is unclear if this is a definitive risk factor as it has been identified in only one family.

Frequently Asked Questions

Current evidence is mixed. Some studies suggest the S18Y variant may lower risk, especially in younger adults, but other large cohorts have found no protective effect. It is not a guarantee of immunity, and other genetic and environmental factors still influence Parkinson’s risk.
Testing for UCHL1 variants is optional and usually not part of standard Parkinson’s panels because the gene’s contribution to disease risk is modest. Discuss with a neurologist or genetic counselor; testing may be considered if you want comprehensive risk assessment or if a specific family mutation (e.g., I93M) has been identified.
t present, UCHL1 status does not alter standard Parkinson’s treatments such as levodopa, dopamine agonists, or deep brain stimulation. Research is ongoing to develop therapies targeting the ubiquitin‑proteasome system, but these are experimental and not yet clinically available.
General neuroprotective measures—regular aerobic exercise, a Mediterranean‑style diet rich in antioxidants, adequate sleep, and avoidance of neurotoxins (e.g., pesticides, excessive alcohol)—are recommended for anyone at risk for Parkinson’s. While they do not specifically “fix” UCHL1 activity, they support overall neuronal health.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.